---
document_datetime: 2025-11-23 10:19:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/eperzan.html
document_name: eperzan.html
version: success
processing_time: 0.1061668
conversion_datetime: 2025-12-26 09:41:50.553387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Eperzan

[RSS](/en/individual-human-medicine.xml/65928)

##### Withdrawn

This medicine's authorisation has been withdrawn

albiglutide

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Eperzan](#news-on)
- [More information on Eperzan](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 29 October 2018, the European Commission withdrew the marketing authorisation for Eperzan (albiglutide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, GlaxoSmithKline Trading Services Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Eperzan was granted marketing authorisation in the EU on 21 March 2014 for the treatment of type 2 diabetes mellitus.

The European Public Assessment Report (EPAR) for Eperzan is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Eperzan : EPAR - Summary for the public

Reference Number: EMA/57956/2014

English (EN) (562.4 KB - PDF)

**First published:** 10/04/2014

**Last updated:** 20/02/2019

[View](/en/documents/overview/eperzan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-127)

български (BG) (624.69 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/bg/documents/overview/eperzan-epar-summary-public_bg.pdf)

español (ES) (542.87 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/es/documents/overview/eperzan-epar-summary-public_es.pdf)

čeština (CS) (607.9 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/cs/documents/overview/eperzan-epar-summary-public_cs.pdf)

dansk (DA) (541.22 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/da/documents/overview/eperzan-epar-summary-public_da.pdf)

Deutsch (DE) (544.32 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/de/documents/overview/eperzan-epar-summary-public_de.pdf)

eesti keel (ET) (540.43 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/et/documents/overview/eperzan-epar-summary-public_et.pdf)

ελληνικά (EL) (630.45 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/el/documents/overview/eperzan-epar-summary-public_el.pdf)

français (FR) (547.85 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fr/documents/overview/eperzan-epar-summary-public_fr.pdf)

hrvatski (HR) (562.04 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hr/documents/overview/eperzan-epar-summary-public_hr.pdf)

italiano (IT) (540.11 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/it/documents/overview/eperzan-epar-summary-public_it.pdf)

latviešu valoda (LV) (622.24 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/lv/documents/overview/eperzan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (565.35 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/lt/documents/overview/eperzan-epar-summary-public_lt.pdf)

magyar (HU) (595.19 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hu/documents/overview/eperzan-epar-summary-public_hu.pdf)

Malti (MT) (608.19 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/mt/documents/overview/eperzan-epar-summary-public_mt.pdf)

Nederlands (NL) (541.07 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/nl/documents/overview/eperzan-epar-summary-public_nl.pdf)

polski (PL) (605.32 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pl/documents/overview/eperzan-epar-summary-public_pl.pdf)

português (PT) (542.53 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pt/documents/overview/eperzan-epar-summary-public_pt.pdf)

română (RO) (565.97 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/ro/documents/overview/eperzan-epar-summary-public_ro.pdf)

slovenčina (SK) (606.51 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sk/documents/overview/eperzan-epar-summary-public_sk.pdf)

slovenščina (SL) (598.09 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sl/documents/overview/eperzan-epar-summary-public_sl.pdf)

Suomi (FI) (540.84 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fi/documents/overview/eperzan-epar-summary-public_fi.pdf)

svenska (SV) (540.92 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sv/documents/overview/eperzan-epar-summary-public_sv.pdf)

## Product information

Eperzan : EPAR - Product Information

English (EN) (1.3 MB - PDF)

**First published:** 10/04/2014

**Last updated:** 20/02/2019

[View](/en/documents/product-information/eperzan-epar-product-information_en.pdf)

[Other languages (22)](#file-language-dropdown-148)

български (BG) (3.78 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/bg/documents/product-information/eperzan-epar-product-information_bg.pdf)

español (ES) (1.31 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/es/documents/product-information/eperzan-epar-product-information_es.pdf)

čeština (CS) (2.61 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/cs/documents/product-information/eperzan-epar-product-information_cs.pdf)

dansk (DA) (1.28 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/da/documents/product-information/eperzan-epar-product-information_da.pdf)

Deutsch (DE) (2.91 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/de/documents/product-information/eperzan-epar-product-information_de.pdf)

eesti keel (ET) (1.28 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/et/documents/product-information/eperzan-epar-product-information_et.pdf)

ελληνικά (EL) (3.79 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/el/documents/product-information/eperzan-epar-product-information_el.pdf)

français (FR) (1.85 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fr/documents/product-information/eperzan-epar-product-information_fr.pdf)

hrvatski (HR) (2.06 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hr/documents/product-information/eperzan-epar-product-information_hr.pdf)

italiano (IT) (2.35 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/it/documents/product-information/eperzan-epar-product-information_it.pdf)

lietuvių kalba (LT) (2.5 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/lt/documents/product-information/eperzan-epar-product-information_lt.pdf)

magyar (HU) (2.8 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hu/documents/product-information/eperzan-epar-product-information_hu.pdf)

Malti (MT) (3.61 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/mt/documents/product-information/eperzan-epar-product-information_mt.pdf)

Nederlands (NL) (1.74 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/nl/documents/product-information/eperzan-epar-product-information_nl.pdf)

norsk (NO) (1.9 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/no/documents/product-information/eperzan-epar-product-information_no.pdf)

polski (PL) (3.46 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pl/documents/product-information/eperzan-epar-product-information_pl.pdf)

português (PT) (2.22 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pt/documents/product-information/eperzan-epar-product-information_pt.pdf)

română (RO) (1.49 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/ro/documents/product-information/eperzan-epar-product-information_ro.pdf)

slovenčina (SK) (2.84 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sk/documents/product-information/eperzan-epar-product-information_sk.pdf)

slovenščina (SL) (2.84 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sl/documents/product-information/eperzan-epar-product-information_sl.pdf)

Suomi (FI) (1.7 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fi/documents/product-information/eperzan-epar-product-information_fi.pdf)

svenska (SV) (1.9 MB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sv/documents/product-information/eperzan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0031 14/09/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Eperzan : EPAR - All Authorised presentations

English (EN) (464.95 KB - PDF)

**First published:** 10/04/2014

**Last updated:** 20/02/2019

[View](/en/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-365)

български (BG) (530.35 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/bg/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_bg.pdf)

español (ES) (464.99 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/es/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (512.08 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/cs/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (461.05 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/da/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (479.46 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/de/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (473.97 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/et/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (515.98 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/el/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_el.pdf)

français (FR) (465.85 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fr/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (480.51 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hr/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (545.36 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/is/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (556.13 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/it/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (511.54 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/lv/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (508.44 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/lt/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (504.72 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/hu/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (511.91 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/mt/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (475.83 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/nl/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (476.21 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/no/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_no.pdf)

polski (PL) (522.9 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pl/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_pl.pdf)

português (PT) (473.83 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/pt/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_pt.pdf)

română (RO) (511.84 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/ro/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (511.2 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sk/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (496.05 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sl/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (470.96 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/fi/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (473.85 KB - PDF)

**First published:**

10/04/2014

**Last updated:**

20/02/2019

[View](/sv/documents/all-authorised-presentations/eperzan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Eperzan Active substance albiglutide International non-proprietary name (INN) or common name albiglutide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ04

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:

Monotherapy

When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.

Add-on combination therapy

In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).

## Authorisation details

EMA product number EMEA/H/C/002735 Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 22/01/2014 Marketing authorisation issued 20/03/2014 Withdrawal of marketing authorisation 29/10/2018 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Eperzan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (656.63 KB - PDF)

**First published:** 06/10/2014

**Last updated:** 20/02/2019

[View](/en/documents/procedural-steps-after/eperzan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Eperzan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/705417/2013

English (EN) (4 MB - PDF)

**First published:** 10/04/2014

**Last updated:** 20/02/2019

[View](/en/documents/assessment-report/eperzan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Eperzan

Adopted

Reference Number: EMA/CHMP/20616/2014

English (EN) (523.8 KB - PDF)

**First published:** 24/01/2014

**Last updated:** 20/02/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-eperzan_en.pdf)

#### News on Eperzan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

#### More information on Eperzan

- [EMEA-001175-PIP01-11-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001175-pip01-11-m04)
- [An Observational Study of the Risk of Acute Pancreatitis in Subjects Exposed to Albiglutide, Other GLP-1 Agonists or DPP-4 Inhibitors Compared to Other Antidiabetic Agents (201804) - post-authorisation study](https://catalogues.ema.europa.eu/study/48256)
- [A cohort study to investigate the prescribing of albiglutide among women of child-bearing age who have type 2 diabetes (201795) - post-authorisation study](https://catalogues.ema.europa.eu/study/42105)
- [An Observational Study of the Risk of Malignant Neoplasms and Malignant Neoplasms of Special Interest (Thyroid and Pancreatic Cancer) in Subjects Treated with Albiglutide Compared to Those Treated with Other Antidiabetic Agents (201805) - post-authorisation study](https://catalogues.ema.europa.eu/study/36771)

**This page was last updated on** 20/02/2019

## Share this page

[Back to top](#main-content)